A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins

Name: A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins
Published: 2022
License: Public Domain

Speransa Therapeutics · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

beta coronavirus cov sars

sars-cov-2 infection, sars-cov-2, coronavirus, covid-19, prime-2-cov_beta, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins

Related documents